Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Emisphere Technologies has said that recent animal studies have demonstrated proof of concept that absorption of oral vitamin B12 using the company's proprietary eligen technology was 15-30 times greater than with the same dose of oral vitamin B12 administered alone.
Subscribe to our email newsletter
Emisphere’s eligen technology is the basis of the company’s unique and improved delivery of therapeutic molecules and pharmaceutical compounds.
Michael Novinski, president and CEO of Emisphere, said: “This data demonstrates an exciting potential commercial avenue for our technology that can have a positive impact on the lives of many patients and Emisphere.”